Lack of evidence for the efficacy of memantine in mild Alzheimer disease

Archives of Neurology

Volumn 68, Issue 8, 2011, Pages 991-998

  Schneider, Lon S ^a   Dagerman, Karen S ^a   Higgins, Julian P T ^b   McShane, Rupert ^c  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MEMANTINE; PLACEBO;

ALZHEIMER DISEASE; ALZHEIMER DISEASE ASSESSMENT SCALE COGNITIVE SUBSCALE; ALZHEIMER DISEASE COOPERATIVE STUDY ACTIVITIES OF DAILY LIVING SCALE; ARTICLE; CLINICAL STUDY; CLINICIAN INTERVIEW BASED IMPRESSION OF CHANGE PLUS CAREGIVER INPUT; DISEASE SEVERITY; DRUG EFFICACY; HUMAN; META ANALYSIS; NEUROPSYCHIATRIC INVENTORY; NEUROPSYCHOLOGICAL TEST; PRIORITY JOURNAL; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

ALZHEIMER DISEASE; COGNITION DISORDERS; EVIDENCE-BASED MEDICINE; EXCITATORY AMINO ACID ANTAGONISTS; HUMANS; MEMANTINE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 79959389773     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneurol.2011.69     Document Type: Article

References (51)

1. McClendon MJ, Hernandez S, Smyth KA, Lerner AJ. Memantine and acetylcholinesterase inhibitor treatment in cases of CDR 0.5 or questionable impairment. J Alzheimers Dis. 2009;16(3):577-583.
2. McManus T. Stakeholder insight: Alzheimer's disease-prescribing trends indicate that neurologists are not adhering to guidelines. Datamonitor Web site. http://www.marketresearch.com/vendors/viewVendor.asp?VendorID=72. Published December 2006. Accessed February 25, 2011.
3. Schneider LS, Insel PS, Weiner MW. Treatment with cholinesterase inhibitors and memantine of patients in the Alzheimer's Disease Neuroimaging Initiative. Arch Neurol. 2011;68(1):58-66.
4. Schneider LS, Sano M. Current Alzheimer's disease clinical trials: methods and placebo outcomes. Alzheimers Dement. 2009;5(5):388-397.
5. Weinstein AM, Barton C, Ross L, Kramer JH, Yaffe K. Treatment practices of mild cognitive impairment in California Alzheimer's Disease Centers. J Am Geriatr Soc. 2009;57(4):686-690.
6. Roberts JS, Karlawish JH, Uhlmann WR, Petersen RC, Green RC. Mild cognitive impairment in clinical care: a survey of American Academy of Neurology members. Neurology. 2010;75(5):425-431.
7. Folstein MF, Folstein SE, McHugh PR. "Mini-Mental State": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189-198.
8. Namenda [package insert]. Forest Laboratories, Inc Web site. http://www.frx.com/pi/namenda-pi.pdf. Accessed June 6, 2009.
9. Forest receives non-approvable letter for expanded Namenda indication. Drug Industry Daily, vol. 4, no. 145. FDANews Web site. http://www.fdanews.com/ newsletter/article?issueId=7842&articleId=74659. Published July 26, 2005. Accessed July 9, 2007.
10. Forest Laboratories announces FDA decision on supplemental new drug application for Namenda. PRNewswire. Forest Laboratories, Inc Web site. http://www.frx.com/news/PressRelease.aspx?ID=734345. Published July 25, 2005. Accessed February 25, 2011.
11. Peskind ER, Potkin SG, Pomara N, et al. Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial. Am J Geriatr Psychiatry. 2006;14(8):704-715. (Pubitemid 44196270)
12. Porsteinsson AP, Grossberg GT, Mintzer J, Olin JT; Memantine MEM-MD-12 Study Group. Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial. Curr Alzheimer Res. 2008;5(1):83-89. (Pubitemid 351536358)
13. Bakchine S, Loft H. Memantine treatment in patients with mild to moderate Alzheimer's disease: results of a randomised, double-blind, placebo-controlled 6-month study. J Alzheimers Dis. 2007;11(4):471-479. (Pubitemid 47094022)
14. Winblad B, Jones RW, Wirth Y, Stöffler A, Möbius HJ. Memantine in moderate to severe Alzheimer's disease: a meta-analysis of randomised clinical trials. Dement Geriatr Cogn Disord. 2007;24(1):20-27. (Pubitemid 46985287)
15. Axura product information: annex I: summary of product characteristics. Published April 27, 2006. European Medicines Agency Web site. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR---Product-Information/ human/000378/WC500029678.pdf. Accessed March 4, 2011.
16. European public assessment report: Axura-H-C-378-II-11 scientific discussion. Published November 15, 2005. European Medicines Agency Web site. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR---Scientific- Discussion---Variation/human/000378/WC500029677.pdf. Accessed March 4, 2011.
17. Doody RS, Tariot PN, Pfeiffer E, Olin JT, Graham SM. Meta-analysis of six-month memantine trials in Alzheimer's disease. Alzheimers Dement. 2007;3(1):7-17. (Pubitemid 46076022)
18. McShane R, Areosa Sastre A, Minakaran N. Memantine for dementia [update of: Cochrane Database Syst Rev. 2005;(2):CD003154]. Cochrane Database Syst Rev. 2006;(2):CD003154.
19. Mohs RC, Knopman D, Petersen RC, et al. Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's Disease Assessment Scale that broaden its scope: the Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord. 1997;11(suppl 2):S13-S21.
20. Schneider LS, Olin JT, Doody RS, et al. Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change: the Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord. 1997;11(suppl 2):S22-S32.
21. Galasko D, Bennett D, Sano M, et al. An inventory to assess activities of daily living for clinical trials in Alzheimer's disease: the Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord. 1997;11(suppl 2):S33-S39.
22. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994;44(12):2308-2314.
23. Review Manager (RevMan) [computer program]. Version 5.0. Copenhagen, Denmark: The Nordic Cochrane Centre, The Cochrane Collaboration; 2008.
24. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557-560. (Pubitemid 37088507)
25. Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions. Chichester, England: John Wiley & Sons; 2008.
26. JAPIC clinical trials information. Confirmatory randomized, double-blind, placebo-controlled, parallel-group study of SUN Y7017 (memantine hydrochloride) in patients with mild to moderate dementia of the Alzheimer's type. Japan Pharmaceutical Information Center Web site. http://www.clinicaltrials.jp/user/ showCteDetailE.jsp?japicId=JapicCTI-050079. Accessed February 25, 2011.
27. Schmidt R, Ropele S, Pendl B, et al. Longitudinal multimodal imaging in mild to moderate Alzheimer disease: a pilot study with memantine. J Neurol Neurosurg Psychiatry. 2008;79(12):1312-1317.
28. Wilkinson D, Fox N, Barkhof F, Phul R, Scheltens P. Evaluating the effect of memantine on the rate of brain atrophy in patients with Alzheimer's disease: a multicentre imaging study using a patient enrichment strategy. Poster presented at: 14th International Congress of the International Psychogeriatric Association; September 1-5, 2009; Montréal, Canada.
29. Wilkinson D, Andersen HF. Analysis of the effect of memantine in reducing the worsening of clinical symptoms in patients with moderate to severe Alzheimer's disease. Dement Geriatr Cogn Disord. 2007;24(2):138-145. (Pubitemid 47094073)
30. Maidment ID, Fox CG, Boustani M, Rodriguez J, Brown RC, Katona CL. Efficacy of memantine on behavioral and psychological symptoms related to dementia: a systematic meta-analysis. Ann Pharmacother. 2008;42(1):32-38.
31. Study no. MEM-MD-10. A randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of Memantine in patients with mild to moderate dementia of the Alzheimer's type. Forest Laboratories, Inc Web site. http://www.forestclinicaltrials.com/CTR/CTRController/CTRViewPdf?-file-id=scsr/ SCSR-MEM-MD-10-final.pdf. Accessed March 4, 2011.
32. Study no. MEM-MD-12. A randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of Memantine in patients with mild to moderate dementia of the Alzheimer's type. Forest Laboratories, Inc Web site. http://www.forestclinicaltrials.com/CTR/CTRController/CTRViewPdf?-file-id=scsr/ SCSR-MEM-MD-12-final.pdf. Accessed March 4, 2011.
33. Clinical trial report summary: study 99679. Title of study: a randomised, double-blind, placebo-controlled evaluation of the efficacy and safety of memantine in patients with mild to moderate dementia of the Alzheimer's type. H. Lundbeck A/S Web site. http://www.lundbecktrials.com/Data/PDFs/99679-CTRS- Final%20for%20upload-15Aug2007.pdf. Accessed September 1, 2010.
34. Loy C, Schneider L. Galantamine for Alzheimer's disease and mild cognitive impairment [update of: Cochrane Database Syst Rev. 2004;(4):CD001747]. Cochrane Database Syst Rev. 2006;(1):CD001747.
35. Birks J, Harvey RJ. Donepezil for dementia due to Alzheimer's disease [update of: Cochrane Database Syst Rev. 2003;(3):CD001190]. Cochrane Database Syst Rev. 2006;(1):CD001190.
36. Birks J, Grimley Evans J, Iakovidou V, Tsolaki M. Rivastigmine for Alzheimer's disease [update of: Cochrane Database Syst Rev. 2000;(2):CD001191]. Cochrane Database Syst Rev. 2000;(4):CD001191.
37. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev. 2006;(1):CD005593.
38. Reisberg B, Doody R, Stöffler A, Schmitt F, Ferris S, Möbius HJ; Memantine Study Group. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med. 2003;348(14):1333-1341. (Pubitemid 36384100)
39. Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I; Memantine Study Group. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA. 2004;291(3):317-324. (Pubitemid 38101604)
40. van Dyck CH, Tariot PN, Meyers B, Malca Resnick E; for the Memantine MEM-MD-01 Study Group. A 24-week randomized, controlled trial of memantine in patients with moderate-to-severe Alzheimer disease. Alzheimer Dis Assoc Disord. 2007;21(2):136-143. (Pubitemid 46878975)
41. Schmitt FA, Ashford W, Ernesto C, et al. The severe impairment battery: concurrent validity and the assessment of longitudinal change in Alzheimer's disease: the Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord. 1997;11(suppl 2):S51-S56.
42. Schneider LS. Commentary on "Meta-analysis of six-month memantine trials in Alzheimer's disease": wuthering forest plots: distinguishing the forest from the plots. Alzheimers Dement. 2007;3(1):18-20. (Pubitemid 46076023)
43. Knopman DS. Commentary on "Meta-analysis of six-month memantine trials in Alzheimer's disease": memantine has negligible benefits in mild to moderate Alzheimer's disease. Alzheimers Dement. 2007;3(1):21-22. (Pubitemid 46076024)
44. Perneczky R, Wagenpfeil S, Komossa K, Grimmer T, Diehl J, Kurz A. Mapping scores onto stages: mini-mental state examination and clinical dementia rating. Am J Geriatr Psychiatry. 2006;14(2):139-144. (Pubitemid 43227636)
45. Kurz A, Farlow M, Quarg P, Spiegel R. Disease stage in Alzheimer disease and treatment effects of rivastigmine. Alzheimer Dis Assoc Disord. 2004;18(3):123-128. (Pubitemid 39202187)
46. Farlow M. Moderate to severe Alzheimer disease: definition and clinical relevance. Neurology. 2005;65:S1-S4. (Pubitemid 41362107)
47. Seltzer B, Zolnouni P, Nunez M, et al Donepezil "402" Study Group. Efficacy of donepezil in early-stage Alzheimer disease: a randomized placebo-controlled trial [published correction appears in Arch Neurol. 2005;62(5):825]. Arch Neurol. 2004;61(12):1852-1856. (Pubitemid 39612945)
48. Clinical trial report summary: study 10112. Title of study: a 1-year randomised, double-blind, placebo-controlled study to evaluate the effects of memantine on the rate of brain atrophy in patients with Alzheimer's Disease. H. Lundbeck A/S Web site. http://www.lundbecktrials.com/Data/PDFs/10112- Final%20CTRS-28May2010.pdf. Accessed September 1, 2010.
49. MAGD: memantine for agitation in dementia. UK Clinical Research Network Study Web site. http://public.ukcrn.org.uk/search/StudyDetail.aspx?StudyID=3986. Accessed September 1, 2010.
50. Efficacy and safety of memantine in moderate to severe Alzheimer's disease. ClinicalTrials. gov Web site. http://www.clinicaltrials.gov/ct2/show/ NCT00857649. Accessed September 1, 2010.
51. Ferris S, Schneider LS, Farmer M, Kay G, Crook T. A double-blind, placebo-controlled trial of memantine in age-associated memory impairment (memantine in AAMI). Int J Geriatr Psychiatry. 2007;22(5):448-455. (Pubitemid 46831689)